Table 3.
Percentage of newly-diagnosed CML patients meeting TKI discontinuation criteria and achieving stable TFR. Discontinuation and TFR criteria are arbitrarily defined, differ between studies and are often not pre-specified. Data are from retrospective analyses.
| Ref | Study | Initial TKI | N | Median follow-up (y) | Met discontinuation criteria | Discontinued | Achieved Stable TFR |
|---|---|---|---|---|---|---|---|
| Branford et al. [22] | Adelaide | IM 400/600/800 | 423 | 8 | 37% | NR | NR |
| Geelen et al. [90] | Dutch | IM 400 (75%), 2GTKIs (25%) | 382 | 10 | 31% | 10% | NR |
| Flygt et al. [48] | Swedish | Mainly IM 400 | 548 | 9 | NR | 23% | 12% |
| Etienne et al. [43] | French | Mainly IM 400 | 398 | 7 | 10%–55% | 46% | 12% |
| Kantarjian et al. [26] | ENESTnd | IM 400 | 283 | 10 | 30% | NR | NR |
| Guilhot et al. [27] | French SPIRIT | IM 400 + LDAC or + IFNα or IM 600 | 787 | 13.5 | NR | 44% | 18% |
| Gugliotta et al. [92] | GIMEMA | NIL 800 | 73 | 10 | NR | 33% | 25% |
| Kantarjian et al. [26] | ENESTnd | NIL 600 | 282 | 10 | 49% | NR | NR |
| Kantarjian et al. [26] | ENESTnd | NIL 800 | 281 | 10 | 47% | NR | NR |
TKI doses are in mg/d. Percentages are rounded.
Abbreviations as in Table 1. 2GTKIs: second-generation TKIs.